-
公开(公告)号：US20050220757A1
公开(公告)日：2005-10-06
申请号：US10499100
申请日：2002-12-16
IPC分类号： C12N15/09 , A61K38/00 , A61K38/19 , A61K45/00 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P37/06 , C07K14/47 , C07K14/52 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/19 , C12P21/02
CPC分类号： C07K14/523 , A61K38/00
摘要： Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.
摘要翻译： 在保守的共有序列中含有非保守取代的特异性CC-趋化因子的突变体作为CC-趋化因子拮抗剂，可以有效地用于治疗自身免疫性和炎性疾病，癌症和病毒或细菌感染。 特别优选的是具有SEQ ID NO：1,2,3或4的氨基酸序列的RANTES / CCL5突变体。
-
公开(公告)号：US07740833B2
公开(公告)日：2010-06-22
申请号：US10573625
申请日：2004-10-18
申请人： Amanda Proudfoot , Jeffrey Shaw , Zoe Johnson
发明人： Amanda Proudfoot , Jeffrey Shaw , Zoe Johnson
CPC分类号： C07K14/523 , A61K38/00 , C07K2319/30 , G01N33/6863 , G01N2500/00 , G01N2800/24 , G01N2800/285
摘要： Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in pharmaceutical compositions for the treatment of inflammatory, autoimmune, or infectious diseases.
摘要翻译： 在二聚化界面中具有改变氢键图案和作为专性单体的单一氨基酸取代的同源二聚体形成趋化因子（例如人CCL2）的变体可以拮抗天然趋化因子并且在体内具有抗炎活性。 这些变体可用作用于治疗炎性，自身免疫性或感染性疾病的药物组合物中的活性成分。
-
公开(公告)号：US20090022657A1
公开(公告)日：2009-01-22
申请号：US10573726
申请日：2004-10-22
申请人： Amanda Proudfoot , Jeffrey Shaw
发明人： Amanda Proudfoot , Jeffrey Shaw
CPC分类号： C07K14/5421 , A61K38/00
摘要： Novel antagonists of the chemokine CXCL8 (also known as Interleukin-8) can be obtained by generating mutants having specific combinations of non-conservative substitutions of basic amino acids located in the C-terminal region. Compounds prepared in accordance with the present invention can be used to block CXCL8 activity in vivo, thereby providing therapeutic compositions for use in the treatment or prevention of CXCL8-related diseases.
摘要翻译： 趋化因子CXCL8（也称为白细胞介素-8）的新型拮抗剂可以通过产生具有位于C-末端区域的碱性氨基酸的非保守取代的特异性组合的突变体来获得。 根据本发明制备的化合物可用于在体内阻断CXCL8活性，从而提供用于治疗或预防CXCL8相关疾病的治疗组合物。
-
公开(公告)号：US20070280958A1
公开(公告)日：2007-12-06
申请号：US10573625
申请日：2004-10-18
申请人： Amanda Proudfoot , Jeffrey Shaw , Zoe Johnson
发明人： Amanda Proudfoot , Jeffrey Shaw , Zoe Johnson
IPC分类号： A61K38/19 , A61P1/06 , A61P11/00 , A61P13/12 , A61P17/00 , A61P19/00 , A61P21/00 , A61P25/00 , A61P35/00 , A61P37/00 , C07K14/52 , C12P21/00
CPC分类号： C07K14/523 , A61K38/00 , C07K2319/30 , G01N33/6863 , G01N2500/00 , G01N2800/24 , G01N2800/285
摘要： Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in pharmaceutical compositions for the treatment of inflammatory, autoimmune, or infectious diseases.
摘要翻译： 在二聚化界面中具有改变氢键图案和作为专性单体的单一氨基酸取代的同源二聚体形成趋化因子（例如人CCL2）的变体可以拮抗天然趋化因子并且在体内具有抗炎活性。 这些变体可用作用于治疗炎性，自身免疫性或感染性疾病的药物组合物中的活性成分。
-
公开(公告)号：US07553483B2
公开(公告)日：2009-06-30
申请号：US10499100
申请日：2002-12-16
CPC分类号： C07K14/523 , A61K38/00
摘要： Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.
摘要翻译： 在保守的共有序列中含有非保守取代的特异性CC-趋化因子的突变体作为CC-趋化因子拮抗剂，可以有效地用于治疗自身免疫性和炎性疾病，癌症和病毒或细菌感染。 特别优选的是具有SEQ ID NO：1,2,3或4的氨基酸序列的RANTES / CCL5突变体。
-
6.发明申请公开(公告)号：US20080253996A1
公开(公告)日：2008-10-16
申请号：US12067224
申请日：2006-10-30
CPC分类号： A61K38/215 , A61K38/195 , A61K47/60 , A61K2300/00
摘要： The invention relates to the use of SDF-1, or of an agonist of SDF-1 activity, for the treatment and/or prevention of a neurological disease.
摘要翻译： 本发明涉及SDF-1或SDF-1活性激动剂在治疗和/或预防神经系统疾病中的用途。
-
公开(公告)号：US07393660B2
公开(公告)日：2008-07-01
申请号：US10583218
申请日：2004-12-21
CPC分类号： C07K14/43527
摘要： A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.
摘要翻译： 从R us唾液中分离出一种新型CC-趋化因子结合蛋白。 根据本发明制备的化合物可用作抗炎化合物和用于治疗或预防CC趋化因子相关疾病。
-
公开(公告)号：US20070004906A1
公开(公告)日：2007-01-04
申请号：US10510658
申请日：2003-04-09
CPC分类号： C07K14/523 , A61K38/00
摘要： Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of diseases related to an undesirable activity of MCP proteins such, such as inflammatory disease, autoimmune diseases, vascular diseases, and cancer.
摘要翻译： MCP蛋白特别是MCP-1蛋白的新型拮抗剂可以通过产生MCP突变体获得，其MCP位点位于MCP蛋白的N-末端，其在非保守取代之后被消除。 根据本发明制备的化合物可用于治疗或预防与MCP蛋白质不期望的活性相关的疾病，例如炎性疾病，自身免疫性疾病，血管疾病和癌症。
-
公开(公告)号：US20080227711A1
公开(公告)日：2008-09-18
申请号：US12067221
申请日：2006-10-30
申请人： Amanda Proudfoot , Christine Power
发明人： Amanda Proudfoot , Christine Power
CPC分类号： C07K14/43527 , A61K38/00
摘要： A novel CXC-chemokine binding protein is cloned from the salivary glands of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immuno-modulatory compounds and in the treatment or prevention of CXC-chemokine-related diseases.
摘要翻译： 一种新型的CXC-趋化因子结合蛋白是从唾液分枝杆菌的唾液腺克隆出来的。 根据本发明制备的化合物可用作抗炎和免疫调节化合物以及用于治疗或预防CXC-趋化因子相关疾病。
-
公开(公告)号：US07425324B2
公开(公告)日：2008-09-16
申请号：US10510658
申请日：2003-04-09
CPC分类号： C07K14/523 , A61K38/00
摘要： Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of diseases related to an undesirable activity of MCP proteins such, such as inflammatory disease, autoimmune diseases, vascular diseases, and cancer.
摘要翻译： MCP蛋白特别是MCP-1蛋白的新型拮抗剂可以通过产生MCP突变体获得，其MCP位点位于MCP蛋白的N-末端，其在非保守取代之后被消除。 根据本发明制备的化合物可用于治疗或预防与MCP蛋白质不期望的活性相关的疾病，例如炎性疾病，自身免疫性疾病，血管疾病和癌症。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.023 秒)